Actualités Small Pharma Inc - DMT | Actions TSX Venture Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to its...

Small Pharma Reports Fiscal Second Quarter 2024 Highlights

• Shareholders overwhelmingly vote in favour of Cybin’s acquisition of Small Pharma, supporting the combined...

Small Pharma Obtains Final Order Approving Arrangement

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (“Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies...

Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders

• Shareholders overwhelmingly vote in favour of Cybin’s acquisition of Small Pharma LONDON, Oct. 12, 2023...

Disposition of Common Shares of Small Pharma Inc.

LONDON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Mr. Peter Rands disposed of an aggregate of 1,532,001 common shares...

Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable...

Cybin va acquérir Small Pharma Inc.

- La transaction portant sur l'ensemble des actions aboutit à la naissance d'un leader international au niveau clinique dans le domaine des...

Cybin to Acquire Small Pharma Inc.

- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics - - Two proprietary, advanced clinical...

Small Pharma Reports Fiscal First Quarter 2024 Highlights

• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential...

Small Pharma Announces SPL028 R&D Strategy Update

• Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential...

Small Pharma Announces Management Team Change

LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or...

Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights

• Multiple clinical milestones achieved including the first proof-of-concept for DMT-based therapies from a...

Small Pharma Announces Significant Developments In Intellectual Property Portfolio

LONDON, May 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or...

Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Small Pharma Inc (DMT)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

DMT Actualités

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

Small Pharma Reports Fiscal Second Quarter 2024 Highlights

Small Pharma Obtains Final Order Approving Arrangement

Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders

Disposition of Common Shares of Small Pharma Inc.

Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

Cybin va acquérir Small Pharma Inc.

Cybin to Acquire Small Pharma Inc.

Small Pharma Reports Fiscal First Quarter 2024 Highlights

Small Pharma Announces SPL028 R&D Strategy Update

Small Pharma Announces Management Team Change

Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights

Small Pharma Announces Significant Developments In Intellectual Property Portfolio

Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Small Pharma Inc (DMT) Actualités

Small Pharma Inc (DMT)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

DMT Actualités

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

Small Pharma Reports Fiscal Second Quarter 2024 Highlights

Small Pharma Obtains Final Order Approving Arrangement

Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders

Disposition of Common Shares of Small Pharma Inc.

Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

Cybin va acquérir Small Pharma Inc.

Cybin to Acquire Small Pharma Inc.

Small Pharma Reports Fiscal First Quarter 2024 Highlights

Small Pharma Announces SPL028 R&D Strategy Update

Small Pharma Announces Management Team Change

Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights

Small Pharma Announces Significant Developments In Intellectual Property Portfolio

Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application